诱导化疗免疫疗法和手术治疗不可切除的第三阶段非小细胞肺癌
Suyu Wang1, Shiqi Hu1, Yifei Zhou1
1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Translational lung cancer research
|October 24, 2025
概括
诱导化疗免疫疗法之后的手术为无法切除的第三阶段非小细胞肺癌 (NSCLC) 患者提供了可比的无疾病和整体存活率. 这种方法证明了良好的安全性和有效性,并提出了可行的替代治疗策略.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 免疫治疗是一种免疫疗法.
背景情况:
- 无法切除的第三阶段非小细胞肺癌 (NSCLC) 的标准治疗包括同时进行化疗和巩固免疫治疗.
- 诱导化疗免疫疗法的有效性和安全性,然后对不可切除的III期NSCLC进行手术仍然不清楚.
研究的目的:
- 评估诱导化疗免疫疗法加手术在患有无法切除的III期NSCLC的患者的疗效和安全性.
- 为了比较不可切除和可切除III期NSCLC患者接受新辅助/诱导化学免疫疗法和手术的结局.
主要方法:
- 查了接受新辅助/诱导化学免疫治疗的I-III期NSCLC患者.
- 使用卡普兰-梅尔法,倾向得分匹配 (PSM) 和Cox回归来进行生存分析 (DFS和OS).
- 分析了外科手术期间的安全性,包括R0切除率,血液损失,住院和死亡率.
主要成果:
- 总共有425名患者被纳入 (278名不可切除的III期,147名可切除的IB-IIIA).
- 在非切除和切除的队列中,在PSM前后,无病生存 (DFS) 和整体生存 (OS) 是可比的.
- 观察到类似的3年DFS (68.7%与66.2%) 和OS (87.8%与89.3%). 周边操作安全指标也显示没有显著差异.
结论:
- 诱导化疗免疫疗法之后的手术为不可切除的III期NSCLC提供了令人满意的无疾病和整体存活率.
- 这种治疗策略显示出良好的安全性,与可切除疾病队列相美.
- 这些发现支持诱导化疗免疫疗法加手术作为不可切除的第三阶段NSCLC的潜在治疗选择.
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K